A prospective, crossover randomized trial of the optimal timing for leucovorin rescue after high-dose methotrexate management in adult non-Hodgkin's lymphoma patients. Issue 8 (2nd July 2020)

• Record Type: Journal Article
• Authors: Peng, Chen; Li, Xueying; Huang, He; Liu, Tingzhi; , Chengcheng; Wang, Zhao; Fang, Xiaojie; Hong, Huangming; Li, Fangfang; Ren, Quanguang; Liu, Shu; Tian, Ying; Lin, Tongyu
• Is Part Of: Leukemia & lymphoma. Volume 61:Issue 8(2020)
• Page Start: 1842
• Page End: 1849
• Publication Date: 2020-07-02
• Subjects: High-dose methotrexate -- leucovorin -- MTX concentration -- non-Hodgkin's lymphoma; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2020.1747061
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: This study aimed to investigate the optimal time of leucovorin rescue for HDMTX in non-Hodgkin's lymphoma (NHL) patients. Ninety-eight patients treated with HDMTX were randomly assigned to receive leucovorin at either 18 or 24 h after initiation of HDMTX infusion during the first cycle and switched to the other mode in the second cycle. All courses achieved an efficacious MTX concentration. Compared to the 18th hour group, the 24th hour group exhibited an increase in incidence of thrombocytopenia (48% versus 34.7%, p = .036) and grade III/IV neutropenia (34.7% versus 21.4%, p = .039). No bleeding occurred and the incidence of fever with grade III/IV neutropenia was low with no difference observed between the two groups. We recommend that with the HDMTX generally used most adult patients with NHL may have greater therapeutic benefit and acceptable toxicity with their LV rescue started at 24 h instead of 18 h.